Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TCR2 Therapeutics Inc. (TCRR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8600-0.1000 (-5.10%)
At close: 04:00PM EDT
1.9500 +0.09 (+4.84%)
After hours: 04:19PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.9600
Open1.9600
Bid1.8000 x 1300
Ask2.4700 x 1100
Day's Range1.8400 - 1.9600
52 Week Range1.8400 - 9.2400
Volume275,766
Avg. Volume263,203
Market Cap71.808M
Beta (5Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-2.8050
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.78
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TCRR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TCR2 Therapeutics Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 7,600 shares of TCR2’s common stock to 2 new non-executive employees. The stock options were granted as an inducement material to the employee

  • Simply Wall St.

    What Kind Of Shareholders Hold The Majority In TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) Shares?

    The big shareholder groups in TCR2 Therapeutics Inc. ( NASDAQ:TCRR ) have power over the company. Institutions often...

  • GlobeNewswire

    TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    - gavo-cel Phase 1 trial dataset anticipated in September 2022- Initial TC-510 Phase 1 data anticipated in 2H 2022 - Expansion of manufacturing capacity and commencement of gavo-cel clinical trial material production at ElevateBio BaseCamp CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for th

Advertisement
Advertisement